TIC10 Analogue is primarily investigated for its potential in cancer therapy due to its ability to activate the tumor suppressor protein TRAIL (TNF-related apoptosis-inducing ligand). It promotes sustained induction of TRAIL across various cancer cell types, leading to apoptosis in tumor cells while sparing normal healthy cells. This selective cytotoxicity makes it a promising candidate for treating resistant cancers, including glioblastoma, pancreatic cancer, and other solid tumors. The compound can cross the blood-brain barrier, which enhances its utility in targeting brain tumors. Additionally, it exhibits oral bioavailability and long-lasting effects in vivo, supporting its development as an oral anticancer agent. Research also explores its use in combination therapies to enhance the efficacy of existing chemotherapeutics and overcome drug resistance.